U.S. Markets closed

FOLD and PTLA: What to Expect from Revenue Growth in Fiscal 2019

Margaret Patrick
FOLD and PTLA: What to Expect from Revenue Growth in Fiscal 2019

Amicus or Portola: Which Is the Best Bet in May?(Continued from Prior Part)Revenue guidanceIn its investor presentation, Amicus Therapeutics (FOLD) has guided for the revenues of its lead asset, Galafold, to fall in the range of $160 million to $180